Our untargeted metabolomics analysis revealed that ALAS2 overexpression significantly altered metabolic pathways in IECs, including protein digestion and absorption, pyrimidine metabolism, vitamin digestion and absorption, central carbon metabolism in cancer, biosynthesis of plant secondary metabolites, and general metabolic pathways. The gene discussed is ALAS2; the disease is cancer.